Skip to main content
Terug
Watch Compare

BriaCell Therapeutics Corp.

Datakwaliteit: 83%
Ook genoteerd als BCTXL NASDAQ BCTXZ NASDAQ
BCTX
NASDAQ Manufacturing Chemicals
€ 4,28
▼ € 0,26 (-5,73%)
Marktkapitalisatie: 31,03 M
Prijs
€ 4,28
Marktkapitalisatie
31,03 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -31,42 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-149,82%
Onder sectorgemiddelde (-53,58%)
ROIC-120,91%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio10,10
Interest Coverage-831,19

Waardering

PE (TTM)
-1,05
Boven sectorgemiddelde (-1,48)
P/B Ratio1,03
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -1,1 -1,5
P/B 1,0 1,6
ROE % -149,8 -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 — 0,0 —

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 -€ 12,11 € 0,04 +100,4%
Q22025 -€ 17,60 -€ 16,40 +6,8%
Q12025 -€ 19,40 -€ 23,30 -20,1%
Q42024 -€ 12,00 -€ 33,00 -175,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -29,64 M
ROE -149,82% ROA -127,01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -31,42 M
ROIC -120,91% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,10
Interest Coverage -831,19 Asset Turnover N/A
Working Capital 28,99 M Tangible Book Value 30,21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,05 Forward P/E N/A
P/B Ratio 1,03 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -101,26%
Market Cap 31,03 M Enterprise Value 1,13 M
Per Share
EPS (Diluted TTM) -63,33 Revenue / Share N/A
FCF / Share -4,33 OCF / Share -4,27
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106,03%
SBC-Adj. FCF -32,50 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -26,31 M -4,79 M -20,30 M -26,84 M
EPS (Diluted) -62,19 -0,29 -1,30 —
Gross Profit — — — —
Operating Income -27,20 M -33,33 M -23,27 M -15,29 M
EBITDA — — — —
R&D Expenses 21,27 M 27,18 M 15,34 M 8,02 M
SG&A Expenses — — — —
D&A — — — 15.272,0
Interest Expense 36.979,0 — 979,0 979,0
Income Tax — — — 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 21,65 M 5,87 M 27,16 M 42,58 M
Total Liabilities — — — —
Shareholders' Equity 17,33 M -2,68 M -3,78 M 10,33 M
Total Debt — — — —
Cash & Equivalents 10,49 M 862.089,0 21,25 M 41,04 M
Current Assets 19,93 M 3,65 M 26,95 M 42,35 M
Current Liabilities 3,98 M 7,46 M 1,80 M 941.087,0